Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia
Blood ( IF 20.3 ) Pub Date : 2024-04-30 , DOI: 10.1182/blood.2024024452 Eric Durot 1 , Damien Roosweil 2 , Adrien Chauchet 3 , Justine Decroocq 4 , Roberta Di Blasi 5 , Thomas Gastinne 6 , Hedi Bensaber 7 , Morgane Cheminant 8 , Caroline Jacquet 9 , Stéphanie Guidez 10 , Francois-Xavier Gros 11 , Emmanuel Bachy 12 , Arthur Coste 13 , Pascale Cony-Makhoul 14 , Steven P. Treon 15 , Alain Jacques Delmer 16 , Ran Reshef 17 , Steven Le Gouill 18 , Jorge J. Castillo 19 , Roch Houot 20
Blood ( IF 20.3 ) Pub Date : 2024-04-30 , DOI: 10.1182/blood.2024024452 Eric Durot 1 , Damien Roosweil 2 , Adrien Chauchet 3 , Justine Decroocq 4 , Roberta Di Blasi 5 , Thomas Gastinne 6 , Hedi Bensaber 7 , Morgane Cheminant 8 , Caroline Jacquet 9 , Stéphanie Guidez 10 , Francois-Xavier Gros 11 , Emmanuel Bachy 12 , Arthur Coste 13 , Pascale Cony-Makhoul 14 , Steven P. Treon 15 , Alain Jacques Delmer 16 , Ran Reshef 17 , Steven Le Gouill 18 , Jorge J. Castillo 19 , Roch Houot 20
Affiliation
Histologic transformation of Waldenström macroglobulinemia (HT-WM) carries a poor prognosis with standard treatments. Here, we report the first series of HT-WM treated with chimeric antigen receptor T cells showing a high efficacy and no unexpected toxicity.
中文翻译:
CD19 CAR T 细胞对转化性瓦尔登斯特伦巨球蛋白血症患者的高效治疗
华氏巨球蛋白血症(HT-WM)的组织学转化采用标准治疗后预后较差。在此,我们报告了第一个系列的用嵌合抗原受体 T 细胞治疗的 HT-WM,显示出高效且无意外毒性。
更新日期:2024-04-30
中文翻译:
CD19 CAR T 细胞对转化性瓦尔登斯特伦巨球蛋白血症患者的高效治疗
华氏巨球蛋白血症(HT-WM)的组织学转化采用标准治疗后预后较差。在此,我们报告了第一个系列的用嵌合抗原受体 T 细胞治疗的 HT-WM,显示出高效且无意外毒性。